Results 1 to 10 of about 24,009 (265)
PLoS ONE, 2023 Lansoprazole, a proton pump inhibitor, can exert antioxidant effects through the induction of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, independently of the inhibition of acid secretion in the gastrointestinal tract.
Naoko Yamagishi +4 more
doaj +4 more sources
Journal of Food and Drug Analysis, 2022 Leishmaniasis remains a serious public health problem in many tropical regions of the world. Among neglected tropical diseases, the mortality rate of leishmaniasis is second only to malaria. All currently approved therapeutics have toxic side effects and
Yash Gupta +7 more
semanticscholar +3 more sources
Gastroenterology, 2022 BACKGROUND & AIMS For decades, proton pump inhibitors (PPIs) have been the mainstay of treatment for erosive esophagitis. The potassium-competitive acid blocker vonoprazan provides more potent acid inhibition than PPIs but data on its efficacy for ...
L. Laine +6 more
semanticscholar +2 more sources
Lansoprazole-Based Colorimetric Chemosensor for Efficient Binding and Sensing of Carbonate Ion: Spectroscopy and DFT Studies [PDF]
Frontiers in Chemistry, 2021 The new benzimidazole based receptor Lansoprazole has been used to detect carbonate anion by naked-eye and Uv-Vis spectroscopy. This receptor revealed visual changes with CO32- anion in ethanol. No detectable color changes were observed upon the addition
M. Darroudi +4 more
semanticscholar +2 more sources
Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT
Health Technology Assessment, 2021 Background: Persistent throat symptoms are commonly attributed to ‘laryngopharyngeal reflux’. Despite a limited evidence base, these symptoms are increasingly being treated in primary care with proton pump inhibitors.
Janet A Wilson +14 more
doaj +2 more sources
Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism [PDF]
Scientific ReportsOur study investigates the effect of vonoprazan on albuminuria in diabetic kidney disease (DKD) patients compared to lansoprazole through a randomized controlled trial. Participants were randomized to receive either lansoprazole 30 mg or vonoprazan 20 mg.
Rabab Mahmoud Ahmed +2 more
doaj +2 more sources
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study [PDF]
Gut, 2017 Objective To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use.Design A phase 3, 24-week ...
Ashida Kiyoshi +8 more
core +3 more sources
Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
Molecular Medicine, 2022 Background Many clinical studies have shown a correlation between proton pump inhibitors (PPIs) and osteoporosis or fractures. The purpose of this study was to establish a murine model of chronic oral PPI administration to verify whether PPIs caused bone
Ziping Cheng +11 more
doaj +2 more sources
Chinese Medical Journal. Background:. Erosive esophagitis (EE) is a gastroesophageal reflux disease characterized by mucosal breaks in the esophagus. Proton pump inhibitors are widely used as maintenance therapy for EE, but many patients still relapse.
Yinglian Xiao +13 more
doaj +2 more sources
A kinetic spectrophotometric method for the determination of lansoprazole in pharmaceutical formulations [PDF]
Journal of the Serbian Chemical Society, 2006 Asimple kinetic spectrophotometric method has been developed for the determination of lansoprazole in pharmaceutical formulations. The method is based on the oxidation of the drug with alkaline potassium permanganate at room temperature. The reaction was
NAFISUR RAHMAN +3 more
doaj +3 more sources